Podcast: What Most Favored Nation Drug Pricing Would Mean for the US James C. RobinsonandRob Lott April 14, 2026

https://www.healthaffairs.org/do/10.1377/hp20260413.536050/full/?utm_campaign=podcast&utm_medium=email&_hsenc=p2ANqtz-9xF9-w2t9yAqk_hEtLViialhSuGyc4wpWv6ri9dKfrFz1TGHmBHrSdfLg6MhyLWdjYJKtsNGx6YPxH9iEg1sUyPoU1ww&_hsmi=416613978&utm_content=ahp&utm_source=well%20read Health Affairs' Rob Lott interviews James Robinson of the University of California Berkeley about his recent paper exploring most favored nation drug pricing, weighing its feasibility, likely effects on drug launch prices, and implications for global pharmaceutical innovation and investment.